To review chronic obstructive pulmonary disease (COPD) and evaluate the role of tiotropium bromide in its treatment.
Data Sources:
MEDLINE was searched for articles published between 1990 and June 2004 that contained the terms tiotropium and chronic obstructive pulmonary disease.
Study Selection/Data Extraction:
Selected studies documented clinical outcomes related to the use of tiotropium bromide and included a complete description of methods and results. These studies were examined to determine the extent of the effect of tiotropium on clinical outcomes involved in COPD.
Data Synthesis:
Tiotropium bromide has a long duration of action and thus can be dosed just once daily. It was found to improve lung function, reduce symptoms, improve health status, and decrease exacerbations compared with both placebo and other bronchodilator medications.
Conclusions:
Tiotropium appears to be a valuable addition to the current therapies available for COPD.
Get full access to this article
View all access options for this article.
References
1.
Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. NHLBI/WHO Global Initiative for Chronic Obstructive Lung Disease (GOLD): updated 2003. www.goldcopd.com (accessed 2004 Jun 11).
AARC Clinical Practice Guidelines. Pulmonary rehabilitation. Respir Care2002; 47: 617–25.
5.
RennardSISerbyCWGhafouriPAFriedmanM.Extended therapy with ipratropium is associated with improved lung function in patients with COPD: A retrospective analysis of data from seven clinical trials. Chest1996; 110: 62–70.
6.
OgaTNishimuraKTuskinoMSatoSHajiroTMichimaM.A comparison of the effects of salbutamol and ipratropium bromide on exercise endurance patients with COPD. Chest2003; 123: 1810–6.
7.
TashkinDPCooperCB. The role of long-acting bronchodilators in the management of stable COPD. Chest2004; 125: 249–59.
8.
NAEPP Expert Panel Report: guidelines for the diagnosis and management of asthma. Update on selected topics 2002. NIH Publication No. 02–5074. June 2003. www.nhlbi.nih.gov/guidelines/asthma/asthmafullrpt.pdf (accessed 2005 Mar 22).
9.
BurgePSCalverleyPMJonesPWSpencerSAndersonJAMaslenTK. Randomised, double blind, placebo controlled study of fluticasone propionate in patients with moderate to severe chronic obstructive pulmonary disease: The ISOLDE trial. BMJ2000; 320: 1297–303.
10.
PanningCADeBisschopM.Tiotropium: An inhaled, long-acting anticholinergic drug for chronic obstructive pulmonary disease. Pharmacotherapy2003; 23: 183–9.
CasaburiRDonohueJFSerbyCWMejogeSSWitekTK. The spirometric efficacy of once-daily dosing with tiotropium in stable COPD: A 13-week multicenter trial. Chest2000; 118: 1294–302.
13.
CasaburiRMahlerDAJonesPWWannerASanPGZuWallackRL, A long-term evaluation of once-daily inhaled tiotropium in chronic obstructive pulmonary disease. Eur Respir J2002; 19: 217–24.
14.
DonohueJFvan NoordJABatemanEDLangleySJLeeAWitekTJ, A 6-month, placebo-controlled study comparing lung function and health status changes in COPD patient treated with tiotropium or salmeterol. Chest2002; 122: 47–55.
15.
LittnerMRIlowiteJSTashkinDPFriedmanMSerbyCWMenjogeSS, Long-acting bronchodilation with once-daily dosing of tiotropium (Spiriva) in stable chronic obstructive pulmonary disease. Am J Respir Crit Care Med2000; 161: 1136–42.
CalverleyPMLeeATowseLvan NoordJWitekTJKelsenS.Effect of tiotropium bromide on circadian variation in airflow limitation in chronic obstructive pulmonary disease. Thorax2003; 58: 855–60.
19.
CelliBWallackRZWangSKestenS.Improvement in resting inspiratory capacity and hyperinflation with tiotropium in COPD patients with increased static lung volume. Chest2003; 124: 1743–8.
20.
HasaniATomsNAgnewJESarnoMHarrisonAJDilworthP.The effect of inhaled tiotropium bromide on lung mucociliary clearance in patients with COPD. Chest2004; 125: 1726–34.
21.
MaesenFPVSmeetsJJSledsensTJHWaldFDMCornelissenPJG. Tiotropium bromide, a new long-acting antimuscarinic bronchodilator: A pharmacodynamic study in patients with chronic obstructive pulmonary disease (COPD). Eur Respir J1995; 8: 1506–13.
22.
TashkinDKestenS.Long-term treatment benefits with tiotropium in COPD patients with and without short-term bronchodilator responses. Chest2003; 123: 1441–9.
23.
BrusascoVHodderRMiravitllesMKorduckiLTowseLKestenS.Health outcomes following treatment for six months with once daily tiotropium compared with twice daily salmeterol in patients with COPD. Thorax2003; 58: 399–404.
24.
CazzolaMDiMarcoFSantusPBoveriBVergaMMateraG, The pharmacodynamic effects of single inhaled doses of formoterol, tiotropium, and their combination in patients with COPD. Pulm Pharmacol Ther2004; 17: 35–9.
25.
van NoordJABantjeTAElandMEKorduckiLCornelissenPJG. A randomized controlled comparison of tiotropium and ipratropium in the treatment of chronic obstructive pulmonary disease. Thorax2000; 55: 289–94.
26.
VinckenWvan NoordJAGreefhorstAPMBantjeTAKestenSKorduckiL, Improved health outcomes in patients with COPD during 1 yr's treatment with tiotropium. Eur Respir J2002; 19: 209–16.
27.
OostenbrinkJBvan-MolkenMP RuttenAlMJvan NoordJAVinckenW.One-year cost-effectiveness of tiotropium versus ipratropium to treat chronic obstructive pulmonary disease. Eur Respir J2004; 23: 241–9.
28.
CasaburiRKukafkaDCooperCGWitekTJKestenS.Improvement in exercise tolerance with the combination of tiotropium and pulmonary rehabilitation in patients with COPD. Chest2005; 127: 809–17.
29.
FlemingT, ed. 2004 Red book. Montvale, NJ: Thomson, 2004.
